CONSISTENT SAFETY ACROSS
LINES OF THERAPY

First Line

Sequoia (Study 304)
COHORT 1: OVERALL INCIDENCE OF ADVERSE REACTIONS (ARs)1,2

Adverse Reactions ARs in ≥10% of Patients Without Del(17p) Pooled Safety Population*
BRUKINSA (n=240) BR (n=227) BRUKINSA (N=1550)
All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%)
Musculoskeletal pain 33 2 17 0.4 30 2
Upper respiratory tract infection 28 1 15 0.9 39 2
Pneumonia 13 5 8 4 20 11
Hemorrhage 27 4 4 0.4 30 4
Hypertension 14 7 5 3 14 7
Rash 24 1 30 5 28 0.9
Bruising 24 0 3 0 23 0.1
Cough 15 0 10 0 19 0.1
Diarrhea 14 0.8 12 0.9 19 2
Constipation 10 0.4 18 0 13 0.3
Nausea 10 0 33 1 11 0.2
Fatigue 14 1 21 2 17 1
Second primary malignancy 13 6 1 0.4 13 6
Headache 12 0 8 0 11 0.4
Dizziness 11 0.8 5 0 11 0.3

*Includes chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, hairy cell leukemia, diffuse large B-cell lymphoma, and Richter’s transformation.2

Includes 3 fatal outcomes.1

Includes 2 fatal outcomes.1


Sequoia (Study 304)
COHORT 2: OVERALL INCIDENCE OF ARs1,2

Adverse Reactions ARs in ≥10% of Patients With Del(17p) Pooled Safety Population*
BRUKINSA (n=111) BRUKINSA (N=1550)
All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%)
Upper respiratory tract infection 38 0 39 2
Pneumonia 20 8 20 11
Musculoskeletal pain 38 3 30 2
Rash 28 0 28 0.9
Bruising 26 0.9 23 0.1
Hemorrhage 28 5 30 4
Hypertension 11 5 14 7
Second primary malignancy 22 6 13 6
Diarrhea 18 0.9 19 2
Nausea 16 0 11 0.2
Constipation 15 0 13 0.3
Abdominal pain 12 2 10 0.6
Cough 18 0 19 0.1
Dyspnea 13 0 8 0.5
Fatigue 14 0.9 17 1
Headache 11 2 11 0.4

*Includes chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, hairy cell leukemia, diffuse large B-cell lymphoma, and Richter’s transformation.2

Includes 1 fatal outcome.1

Includes non-melanoma skin cancer in 13%.1

Sequoia (Study 304): INCIDENCE OF LABORATORY ABNORMALITIES1

Select Lab Abnormalities (≥20%) That Worsened From Baseline in Cohorts 1 and 2

Laboratory Abnormality Cohort 1:
Patients Without Del(17p)
Cohort 2:
Patients With Del(17p)
BRUKINSA (n=239)* BR (n=227) BRUKINSA (N=111)
All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%)
Neutrophils decreased 37 15 80 53 42 19
Hemoglobin decreased 29 3 66 8 26 4
Platelets decreased 27 2 61 11 23 0.9
Leukocytes increased 21§ 21 0.4 0.4 NR NR
Glucose increased 55 7 67 10 52 6
Creatinine increased 22 0.8 18 0.4 27 0.9
Magnesium increased 22 0 14 0.4 31 0
Alanine aminotransferase increased 21 2 23 2 NR NR

*In Cohort 1, the denominator used to calculate the rate varied from 239 to 227 based on the number of patients with a baseline value and at least 1 post-treatment value. Grading is based on NCI CTCAE criteria.

In Cohort 2, the denominator used to calculate the rate varied from 110 to 111 based on the number of patients with a baseline value and at least 1 post-treatment value. Grading is based on NCI CTCAE criteria.

Grade 4, 9%.

§Lymphocytes increased in 15%.

Patients on study were not required to fast for lab tests.

SEQUOIA (STUDY 304): SELECT Adverse Events (AEs) OF SPECIAL INTEREST1-3

Adverse Events SEQUOIA Pooled Safety Population*
BRUKINSA (n=240) BR (n=227) BRUKINSA (N=1550)
All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%)
Fatigue 12 1 15 0.9 17 1
Headache 11 0 7 0 11 0.4
Myalgia 4 0 1 0 4 0.4
Arthralgia 13 0.8 9 0.4 14 0.7
Atrial fibrillation/flutter 3 0.4 3 1 4 2
Hypertension 14 6 11 5 14 7
Major bleeding 5 4 2 2 5 4

*Includes chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, hairy cell leukemia, diffuse large B-cell lymphoma, and Richter’s transformation.2

Includes rates of atrial fibrillation only; does not include flutter.2

Major bleeding includes subdural hematoma or subdural hemorrhage.2

SEQUOIA (STUDY 304):
LOWER RATES OF DOSE REDUCTIONS AND DISCONTINUATION DUE TO AEs3

sequoiasequoia

AE=adverse event; AR=adverse reaction; BR=bendamustine+rituximab; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; NR=not reported.



Second line


ALPINE (STUDY 305): OVERALL INCIDENCE OF ADVERSE REACTIONS (ARs)1,2

Adverse Reactions ARs in ≥10% of Patients Pooled Safety Population*
BRUKINSA (n=324) Ibrutinib (n=324) BRUKINSA (N=1550)
All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%)
Upper respiratory tract infection 27 1 22 1 39 2
Pneumonia 18 9 19 11 20 11
COVID-19 14 7 10 5 5 3
Musculoskeletal pain 26 0.6 28 0.6 30 2
Hemorrhage 24 3 26 4 30 4
Hypertension 19 13 20 13 14 7
Rash 20 1 21 0.9 28 0.9
Bruising 16 0 14 0 23 0.1
Diarrhea 14 2 22 0.9 19 2
Fatigue 13 0.9 14 0.9 17 1
Cough 11 0.3 11 0 19 0.1
Dizziness 10 0 7 0 11 0.3

Rates of hypertension were comparable between BRUKINSA and ibrutinib1

  • A medical history of hypertension was reported in more than half of these patient events for both BRUKINSA and ibrutinib2

*Includes chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, hairy cell leukemia, diffuse large B-cell lymphoma, and Richter’s transformation.2

Includes fatal outcomes: pneumonia (9 patients), COVID-19 (8 patients), and hemorrhage (1 patient).1

Includes fatal outcomes: pneumonia (10 patients), COVID-19 (9 patients), and hemorrhage (2 patients).1


ALPINE (STUDY 305): INCIDENCE OF LAB ABNORMALITIES1

Select Lab Abnormalities (≥20%) That Worsened From Baseline

Laboratory Abnormality
BRUKINSA (n=321) Ibrutinib (n=321)*
All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%)
Neutrophils decreased 43 15 33 16
Hemoglobin decreased 28 4 32 4
Lymphocytes increased 24 19 26 19
Platelets decreased 22 4 24 3
Glucose increased 52 5 29 3
Creatinine increased 26 0 23 0
Phosphate decreased 21 3 13 2
Calcium decreased 21 0.6 29 0

*The denominator used to calculate rates of lab abnormalities varied from 320 to 321 in the ibrutinib arm based on the number of patients with a baseline value and at least 1 post-treatment value. Grading is based on NCI CTCAE criteria.

Patients on study were not required to fast for lab tests.


LOWER RATES OF CARDIAC DISORDERS, INCLUDING AFIB/FLUTTER,
AND NO CARDIAC DEATHS vs IBRUTINIB*4,5

sequoiasequoia

*Assessed by both IRC and investigator with similar results. Median duration of treatment: 28.4 months for BRUKINSA and 24.3 months for ibrutinib.4

Cardiac disorders is a grouped term that includes atrial fibrillation and atrial flutter.4


BRUKINSA
(n=324)
Ibrutinib
(n=324)
Cardiac adverse events 69 (21.3%) 96 (29.6%)
Serious cardiac adverse events 6 (1.9%) 25 (7.7%)
Cardiac adverse events leading to treatment discontinuation* 1 (0.3%) 14 (4.3%)
Fatal cardiac events 0 (0%) 6 (1.9%)

*BRUKINSA cardiac-related discontinuation in 1 patient was for ventricular extrasystoles. Ibrutinib cardiac-related discontinuations were for atrial fibrillation (5), cardiac arrest (2), cardiac failure (2), cardiac failure acute (1), congestive cardiomyopathy (1), myocardial infarction (1), palpitations (1), and ventricular fibrillation (1).4

Assessed by both IRC and investigator with similar results. Median duration of treatment: 28.4 months for BRUKINSA and 24.3 months for ibrutinib.4


SELECT ADVERSE REACTIONS OF SPECIAL INTEREST
IN ALPINE (STUDY 305)1,2,4

Adverse Reactions ALPINE Pooled Safety Population*
BRUKINSA (n=324) Ibrutinib (n=324) BRUKINSA (N=1550)
All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%) All Grades (%) Grade ≥3 (%)
Fatigue 13 0.9 14 0.9 17 1
Headache 8 0 9 0 11 0.4
Myalgia 3 0 4 0 4 0.4
Arthralgia 14 0 15 0.3 14 0.7
Atrial fibrillation and flutter 5 3 13 4 4 2
Hypertension 19 13 20 13 14 7
Major hemorrhage 4 3 4 4 5 4

*Includes chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, hairy cell leukemia, diffuse large B-cell lymphoma, and Richter’s transformation.2

Hematuria was the most common major hemorrhage.2


ALPINE (STUDY 305): LOWer RATES OF DOSE REDUCTIONS AND DISCONTINUATION DUE TO ADVERSE EVENTS (AEs)4

sequoiasequoia

*BRUKINSA cardiac-related discontinuation in 1 patient was for ventricular extrasystoles. Ibrutinib cardiac-related discontinuations were for atrial fibrillation (5), cardiac arrest (2), cardiac failure (2), cardiac failure acute (1), congestive cardiomyopathy (1), myocardial infarction (1), palpitations (1), and ventricular fibrillation (1).

AE=adverse event; afib=atrial fibrillation; AR=adverse reaction; IRC=independent review committee; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events.

Dr Anthony Nguyen discusses the safety profile of BRUKINSA vs ibrutinib in CLL

DISCOVER MORE VIDEOS

Long-term data*

Study 003:

A global supportive Phase 1/2, open-label, single-arm trial that included patients with treatment-naïve or relapsed/refractory CLL/SLL and evaluated ~4 years of safety and ~3 years of efficacy data6

ADVERSE EVENTS OF SPECIAL INTEREST
DECREASED OVER TIME6

Incidence of Treatment-Emergent Adverse Events (TEAEs)
Over Time (Grade ≥3)

sequoiasequoia
  • Atrial fibrillation remained consistently low

  • No new safety signals

  • Low discontinuation rate of 10% over 4 years (N=123)

Overall median duration of treatment: 43 months.

Exploratory long-term analysis; all data are descriptive in nature.

Study 003 was a global supportive Phase 1/2 trial for 1L and 2L CLL.


*Assessed by IRC.

1L=first line; 2L=second line; CLL=chronic lymphocytic leukemia; IRC=independent review committee; SLL=small lymphocytic lymphoma.

EFFICACY ACROSS
LINES OF THERAPY
Efficacy
Flexible
Dosing
Dosing
Personalized
Patient Support
VISIT MYBEIGENE.COM